Ordering and Reimbursement Information

For Ordering Information, Contact Grifols Customer Service:
1-800-243-4153

Contact Information
For reimbursement questions, call the Reimbursement Helpline
at 1-877-827-3462.

For clinical or technical questions, call Medical Information
at 1-800-520-2807.

 

Authorized Distributors:

ASD Healthcare
3101 Gaylord Parkway
Frisco, TX 75034
800-746-6273

BDI Pharma
120 Research Drive
Columbia, SC 29203
800-948-9834

BioCARE
4505 E. Cotton Center Blvd., Ste 100
Phoenix, AZ 85040
800-304-3064

Cardinal Health SPD
305 Tech Park Drive, Ste 113
LaVergne, TN 37086
866-476-1340

FFF Enterprises Inc.
41093 Country Circle Drive
Temecula, CA 92591
800-843-7477

McKesson Plasma and Biologics
401 Mason Road
LaVergne, TN 37086
877-625-2566

National Hospital Specialties (NHS)
65 Commerce Way
Hackensack, NJ 07601
800-344-6087

Novis Pharmaceuticals
5000 SW 75th Avenue, Ste 121
Miami, FL 33155
800-727-6711

 

THROMBATE III® (antithrombin III [human]) is indicated in patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism.

Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment.

Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product.

Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays.

In clinical studies, the most common adverse reactions (≥5% of subjects) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps).

The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.